Regenix Biosciences

Regenix Biosciences is a biopharmaceutical company based in Chennai, India, specializing in the development, formulation, and sterile fill-finish manufacturing of high-quality biosimilars. Operating as a subsidiary of Regenix Drugs Ltd, the company utilizes a state-of-the-art, WHO-GMP certified 30,000 square foot facility in the MEPZ Special Economic Zone to produce biosimilar insulins, GLP-1 analogues, and anticoagulants. Its commercial and approved portfolio includes Insulin Glargine (Sustaglar), Human Insulin (Regular), Biphasic Insulin 30/70, Liraglutide, and Enoxaparin Sodium. Regenix Biosciences is actively expanding its global footprint by targeting over 120 markets with complete CTD/eCTD dossiers and offering B2B partnership models including licensing and contract manufacturing.